Perspective Therapeutics, Inc.
CATX
$1.92
-$0.02-1.03%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -165.63% | -29.20% | 4.72% | 50.22% | -138.27% |
| Total Depreciation and Amortization | 110.91% | 16.96% | 60.67% | 1,469.23% | -109.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,555.83% | 98.78% | 94.21% | -97.12% | 2,009.76% |
| Change in Net Operating Assets | -169.94% | 995.98% | -94.13% | 915.84% | 480.52% |
| Cash from Operations | -890.43% | 137.81% | -164.28% | 253.73% | 10.90% |
| Capital Expenditure | 50.82% | -2,827.39% | 88.81% | -10,093.26% | 60.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -517,912.50% | 98.95% | 94.04% | -- | -- |
| Cash from Investing | -366.09% | -802.49% | 93.03% | -53,042.70% | 60.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 25.00% | -100.00% | 33.33% | 0.00% | 42.86% |
| Issuance of Common Stock | -- | -99.47% | -26.60% | 45,597.80% | 1,554.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -45.06% | -99.49% | -26.60% | 47,152.27% | 35,100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -540.42% | -123.43% | -17.30% | 1,619.49% | 15.39% |